Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?

    Research output: Contribution to journalReview article

    17 Citations (Scopus)

    Abstract

    Dysregulation of the renin-angiotensin-aldosterone system has been associated with a number of age-related pathologies including hypertension, heart failure and chronic kidney disease. More recently, it has been suggested that alterations within the RAAS may contribute to the development of sarcopenia and subsequent decline in physical function. There is growing interest in developing interventions to prevent age-associated decline in muscle function. We postulate that inhibition of the RAAS with the mineralocorticoid antagonist spironolactone may have a role in countering the effects of physical impairment in older people by improving skeletal muscle function. Spironolactone may prevent skeletal myocyte apoptosis, improve vascular endothelial function and enhance muscle contractility by increasing muscle magnesium and sodium-potassium pumps. This article will review the literature underpinning the hypothesis that spironolactone may have a role in maintaining muscle function in older people.

    Original languageEnglish
    Pages (from-to)725-729
    Number of pages5
    JournalClinical Endocrinology
    Volume75
    Issue number6
    DOIs
    Publication statusPublished - Dec 2011

    Keywords

    • CONGESTIVE-HEART-FAILURE
    • CONVERTING ENZYME-INHIBITION
    • LEFT-VENTRICULAR DYSFUNCTION
    • NECROSIS-FACTOR-ALPHA
    • SKELETAL-MUSCLE
    • NITRIC-OXIDE
    • ENDOTHELIAL FUNCTION
    • EXERCISE TOLERANCE
    • MYOCYTE APOPTOSIS
    • CONTROLLED-TRIAL

    Cite this

    @article{52b61b52e8474df9ac9d100a334c3b40,
    title = "Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?",
    abstract = "Dysregulation of the renin-angiotensin-aldosterone system has been associated with a number of age-related pathologies including hypertension, heart failure and chronic kidney disease. More recently, it has been suggested that alterations within the RAAS may contribute to the development of sarcopenia and subsequent decline in physical function. There is growing interest in developing interventions to prevent age-associated decline in muscle function. We postulate that inhibition of the RAAS with the mineralocorticoid antagonist spironolactone may have a role in countering the effects of physical impairment in older people by improving skeletal muscle function. Spironolactone may prevent skeletal myocyte apoptosis, improve vascular endothelial function and enhance muscle contractility by increasing muscle magnesium and sodium-potassium pumps. This article will review the literature underpinning the hypothesis that spironolactone may have a role in maintaining muscle function in older people.",
    keywords = "CONGESTIVE-HEART-FAILURE, CONVERTING ENZYME-INHIBITION, LEFT-VENTRICULAR DYSFUNCTION, NECROSIS-FACTOR-ALPHA, SKELETAL-MUSCLE, NITRIC-OXIDE, ENDOTHELIAL FUNCTION, EXERCISE TOLERANCE, MYOCYTE APOPTOSIS, CONTROLLED-TRIAL",
    author = "Burton, {Louise A.} and McMurdo, {Marion E. T.} and Struthers, {Allan D.}",
    year = "2011",
    month = "12",
    doi = "10.1111/j.1365-2265.2011.04148.x",
    language = "English",
    volume = "75",
    pages = "725--729",
    journal = "Clinical Endocrinology",
    issn = "0300-0664",
    publisher = "Wiley",
    number = "6",

    }

    Mineralocorticoid antagonism : a novel way to treat sarcopenia and physical impairment in older people? / Burton, Louise A.; McMurdo, Marion E. T.; Struthers, Allan D.

    In: Clinical Endocrinology, Vol. 75, No. 6, 12.2011, p. 725-729.

    Research output: Contribution to journalReview article

    TY - JOUR

    T1 - Mineralocorticoid antagonism

    T2 - a novel way to treat sarcopenia and physical impairment in older people?

    AU - Burton, Louise A.

    AU - McMurdo, Marion E. T.

    AU - Struthers, Allan D.

    PY - 2011/12

    Y1 - 2011/12

    N2 - Dysregulation of the renin-angiotensin-aldosterone system has been associated with a number of age-related pathologies including hypertension, heart failure and chronic kidney disease. More recently, it has been suggested that alterations within the RAAS may contribute to the development of sarcopenia and subsequent decline in physical function. There is growing interest in developing interventions to prevent age-associated decline in muscle function. We postulate that inhibition of the RAAS with the mineralocorticoid antagonist spironolactone may have a role in countering the effects of physical impairment in older people by improving skeletal muscle function. Spironolactone may prevent skeletal myocyte apoptosis, improve vascular endothelial function and enhance muscle contractility by increasing muscle magnesium and sodium-potassium pumps. This article will review the literature underpinning the hypothesis that spironolactone may have a role in maintaining muscle function in older people.

    AB - Dysregulation of the renin-angiotensin-aldosterone system has been associated with a number of age-related pathologies including hypertension, heart failure and chronic kidney disease. More recently, it has been suggested that alterations within the RAAS may contribute to the development of sarcopenia and subsequent decline in physical function. There is growing interest in developing interventions to prevent age-associated decline in muscle function. We postulate that inhibition of the RAAS with the mineralocorticoid antagonist spironolactone may have a role in countering the effects of physical impairment in older people by improving skeletal muscle function. Spironolactone may prevent skeletal myocyte apoptosis, improve vascular endothelial function and enhance muscle contractility by increasing muscle magnesium and sodium-potassium pumps. This article will review the literature underpinning the hypothesis that spironolactone may have a role in maintaining muscle function in older people.

    KW - CONGESTIVE-HEART-FAILURE

    KW - CONVERTING ENZYME-INHIBITION

    KW - LEFT-VENTRICULAR DYSFUNCTION

    KW - NECROSIS-FACTOR-ALPHA

    KW - SKELETAL-MUSCLE

    KW - NITRIC-OXIDE

    KW - ENDOTHELIAL FUNCTION

    KW - EXERCISE TOLERANCE

    KW - MYOCYTE APOPTOSIS

    KW - CONTROLLED-TRIAL

    U2 - 10.1111/j.1365-2265.2011.04148.x

    DO - 10.1111/j.1365-2265.2011.04148.x

    M3 - Review article

    C2 - 21699555

    VL - 75

    SP - 725

    EP - 729

    JO - Clinical Endocrinology

    JF - Clinical Endocrinology

    SN - 0300-0664

    IS - 6

    ER -